Betta Pharma

Betta Pharmaceuticals Co., Ltd. is a national high-tech pharmaceutical enterprise established in 2003 and headquartered in Hangzhou, Zhejiang, China. The company operates a fully integrated model spanning drug discovery, R&D, manufacturing, and commercialization, with a primary focus on oncology targeted therapies. Betta independently developed Icotinib hydrochloride (Conmana®), China's first small-molecule anti-cancer drug targeting EGFR mutations, approved in 2011. Subsequent approvals include Ensartinib (Ensacove®) for ALK-mutant NSCLC, Bevacizumab biosimilar, Befotertinib (Surmana®) for third-generation EGFR-TKI resistance, and Vorolanib for advanced renal cell carcinoma. The company has more than 1,700 employees and lists on the Shenzhen Stock Exchange (stock code: 300558.SZ). With R&D expenditure consistently exceeding 40% of total costs, Betta maintains a robust pipeline of 23 clinical-stage programs and 2 NDA-approved candidates, including Ensartinib under FDA review for the US market.